Synermore Biologics (suzhou) Co., Ltd.

This program provides access to SYN023, a combination of two lab-made antibodies (zamerovimab and mazorelvimab) designed to neutralize the rabies virus. It is for people in the United States with confirmed or suspected life-threatening rabies who cannot join other studies or acce…

This study follows 232 children under 18 who received a new antibody injection (zamerovimab and mazorelvimab) plus the rabies vaccine after a severe animal bite. Researchers track whether the children stay rabies-free for up to one year. The goal is to see if this combination pre…